![These highlights do not include all the information needed to use XELJANZ/ XELJANZ XR/XELJANZ Oral Solution safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR/XELJANZ Oral Solution. XELJANZ® (tofacitinib) tablets, for oral These highlights do not include all the information needed to use XELJANZ/ XELJANZ XR/XELJANZ Oral Solution safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR/XELJANZ Oral Solution. XELJANZ® (tofacitinib) tablets, for oral](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=xeljanz-26.jpg&id=727332)
These highlights do not include all the information needed to use XELJANZ/ XELJANZ XR/XELJANZ Oral Solution safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR/XELJANZ Oral Solution. XELJANZ® (tofacitinib) tablets, for oral
![Xeljanz Tofacitinib Tablets : Find Price ,Uses, Side Effects, Interactions, Pictures, Warnings , Reviews India Supply Xeljanz Tofacitinib Tablets : Find Price ,Uses, Side Effects, Interactions, Pictures, Warnings , Reviews India Supply](https://www.letsmeds.com/image/cache/catalog/price/Xeljanz-5mg-667x800.jpg)
Xeljanz Tofacitinib Tablets : Find Price ,Uses, Side Effects, Interactions, Pictures, Warnings , Reviews India Supply
![Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis | Business Wire Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis | Business Wire](https://mms.businesswire.com/media/20160224006053/en/511097/5/2486042_XELJANZ_XR_LOGO_cmyk_lock_up+%281%29.jpg)
Pfizer Announces FDA Approval of XELJANZ® XR (tofacitinib citrate) Extended-Release Tablets, the First and Only Once-Daily Oral JAK Inhibitor Treatment for Rheumatoid Arthritis | Business Wire
![XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA) | Business Wire XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA) | Business Wire](https://mms.businesswire.com/media/20170327005312/en/575040/5/XELJANZ_Registered-03-01.jpg)